Sartorius Stedim Net Income vs. Cash Per Share
SDMHF Stock | USD 176.10 0.00 0.00% |
For Sartorius Stedim profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sartorius Stedim to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sartorius Stedim Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sartorius Stedim's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sartorius Stedim Biotech over time as well as its relative position and ranking within its peers.
Sartorius |
Sartorius Stedim Biotech Cash Per Share vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth. Sartorius Stedim Biotech is currently regarded as top stock in net income category among its peers. It also is currently regarded as top stock in cash per share category among its peers . The ratio of Net Income to Cash Per Share for Sartorius Stedim Biotech is about 236,807,429 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.Sartorius Cash Per Share vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sartorius Stedim |
| = | 414.41 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Sartorius Stedim |
| = | 1.75 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Sartorius Cash Per Share Comparison
Sartorius Stedim is currently under evaluation in cash per share category among its peers.
Sartorius Stedim Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sartorius Stedim, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sartorius Stedim will eventually generate negative long term returns. The profitability progress is the general direction of Sartorius Stedim's change in net profit over the period of time. It can combine multiple indicators of Sartorius Stedim, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 10409 people.
Sartorius Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sartorius Stedim. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sartorius Stedim position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sartorius Stedim's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Sartorius Stedim without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
All Next | Launch Module |
Use Investing Themes to Complement your Sartorius Stedim position
In addition to having Sartorius Stedim in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run JPY Crypto Assets Thematic Idea Now
JPY Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Japanese Yen. The JPY Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize JPY Crypto Assets Theme or any other thematic opportunities.
View All Next | Launch |
Other Information on Investing in Sartorius Pink Sheet
To fully project Sartorius Stedim's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sartorius Stedim Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sartorius Stedim's income statement, its balance sheet, and the statement of cash flows.